切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2019, Vol. 13 ›› Issue (03) : 209 -213. doi: 10.3877/cma.j.issn.1674-0785.2019.03.011

所属专题: 文献

综述

循环LncRNA作为肿瘤生物学标志物的应用研究
杜园园1,(), 李鹏1, 宋凌燕1, 郭旭霞1   
  1. 1. 046000 山西长治,长治医学院附属和平医院检验科
  • 收稿日期:2018-11-28 出版日期:2019-02-01
  • 通信作者: 杜园园
  • 基金资助:
    长治医学院科技启动基金项目(普及项目)(QDZ201653)

Long noncoding RNA as biomarkers for tumors

Yuanyuan Du1,(), Peng Li1, Lingyan Song1, Xuxia Guo1   

  1. 1. Department of Clinical Laboratory, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China
  • Received:2018-11-28 Published:2019-02-01
  • Corresponding author: Yuanyuan Du
  • About author:
    Corresponding author: Du Yuanyuan, Email:
引用本文:

杜园园, 李鹏, 宋凌燕, 郭旭霞. 循环LncRNA作为肿瘤生物学标志物的应用研究[J/OL]. 中华临床医师杂志(电子版), 2019, 13(03): 209-213.

Yuanyuan Du, Peng Li, Lingyan Song, Xuxia Guo. Long noncoding RNA as biomarkers for tumors[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(03): 209-213.

长链非编码RNA(LncRNA)是一组转录本大于200 nt的非编码RNA,参与细胞多个生物学进程,且与各类肿瘤的发生和进展相关联。近年来,肿瘤患者体液中循环LncRNA检测已被证实为有效的诊断肿瘤的方法,且因LncRNA的检测具有非侵入性、创伤小、患者耐受好等特点,优于对传统肿瘤标志物的检测,使LncRNA有望成为肿瘤诊断及预后的新型良好生物学标志物,在临床实践中具有很好的应用前景。本文主要通过对肿瘤患者体液中确定的循环LncRNA表达谱进行分析和总结,综述循环LncRNA作为肿瘤诊断及预后生物学标志物的应用价值。

Long noncoding RNAs (LncRNAs) are a group of noncoding RNA molecules about 200 nt in length, which are involved in the regulation of various cell processes and associated with the development and progression of various cancer types. In recent years, detection of cancer-associated LncRNAs in body fluids of cancer patients has proven as an especially valuable method to effectively diagnose cancer. Compared to conventional tests, LncRNAs have great potential for routine usage in clinical practice due to their relative noninvasiveness. This review focuses on summarizing the perspectives of LncRNA as biomarkers in cancer, based on evaluating their expression profiles in body fluids of cancer patients.

1
Xiao B, Zhang W, Chen L, et al. Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data [J]. Gene, 2018, 658: 28-35.
2
Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? [J]. Oncogene, 2012, 31(43): 4577-4587.
3
Pan X, Zhang G, Gao C. LncRNA PVT1: a novel therapeutic target for cancers [J].Clin Lab, 2018, 64(5): 655-662.
4
Sartori DA, Chan DW. Biomarkers in prostate cancer: what′s new? [J]. Curr Opin Oncol, 2014, 26(3): 259-264.
5
Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer [J]. Eur J Cancer, 2013, 49(13): 2949-2959.
6
Dong L, Lin W, Qi P, et al. Circulating long RNAs in serum extracellular vesicles: their characterization and potential application as biomarkers for diagnosis of colorectal cancer [J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(7): 1158-1166.
7
Gezer U, özgür E, Cetinkaya M, et al. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes [J]. Cell Biol Int, 2014, 38(9): 1076-1079.
8
Qi P, Zhou XY, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives [J]. Mol Cancer, 2016, 15(1): 39.
9
Xie H, Ma H, Zhou D.Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma [J]. Biomed Res Int, 2013, 2013: 136106.
10
Tang J, Jiang R, Deng L, et al. Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma [J]. Oncotarget, 2015, 6(6): 4505-4515.
11
Zhou X, Yin C, Dang Y, et al. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer [J]. Sci Rep, 2015, 5: 11516.
12
Li Q, Shao Y, Zhang X, et al. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer [J]. Tumour Biol, 2015, 36(3): 2007- 2012.
13
Pang Q, Ge J, Shao Y, et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance [J]. Tumour Biol, 2014, 35(6): 5441- 5447.
14
Zhang K, Shi H, Xi H, et al. Genome-wide lncRNA microarray profiling identifies novel circulating lncRNAs for detection of gastric cancer [J]. Theranostics, 2017, 7(1): 213-227.
15
Dong L, Qi P, Xu MD, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls [J]. Int J Cancer, 2015, 137 (5): 1128-1135.
16
Zhang J, Zhang B, Wang T,et al. LncRNA MALAT1 overexpression is an unfavorable prognostic factor in human cancer: evidence from a meta-analysis [J]. Int J Clin Exp Med, 2015, 8 (4): 5499-5505.
17
Guo F, Yu F, Wang J, et al. Expression of MALAT1 in the peripheral whole blood of patients with lung cancer [J]. Biomed Rep, 2015, 3(3): 309-312.
18
Weber DG, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer [J]. BMC Res Notes, 2013, 6: 518.
19
Shao Y, Ye M, Jiang X, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer [J]. Cancer, 2014, 120(21): 3320-3328.
20
Xue WJ, Ying XL, Jiang JH, et al. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis [J]. J Cancer Res Ther, 2014, 10 Suppl: C218-C221.
21
Wang F, Ren S, Chen R, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer [J]. Oncotarget, 2014, 5(22): 11091-11102.
22
Tong YS, Wang XW, Zhou XL, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma [J]. Mol Cancer, 2015, 14: 3.
23
Han Y, Liu Y, Gui Y, et al. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder [J]. J Surg Oncol, 2013, 107(5): 555-559.
24
Svoboda M, Slyskova J, Schneiderova M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients [J]. Carcinogenesis, 2014, 35(7): 1510-1515.
25
Tang H, Wu Z, Zhang J, et al. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis [J]. Mol Med Rep, 2013, 7(3): 761-766.
26
Wang J, Zhou Y, Lu J, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognositic biomarkers for laryngeal squamous cell carcinoma [J]. Med Oncol, 2014, 31(9): 148.
27
Xu N, Chen F, Wang F, et al. Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study [J]. Tumour Biol, 2015, 36(10): 7659-7665.
[1] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[2] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[3] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[4] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[7] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[8] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[9] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[10] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[11] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[12] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[13] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[14] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[15] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
阅读次数
全文


摘要